Will Boehringer-Lilly’s ‘Jardiance’ bring new atmosphere in diabetes treatment market?
Boehringer Ingelheim and Lilly attracted attention as expected to actively enter the SGLT-2 inhibitor market through launching ‘Jardiance(generic name: empagliflozin).’
Boehringer Ingelheim Korea, Lilly Korea and Yuhan Corporation have possessed a diabetes therapy pipeline along with the existin...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
